17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 6, 2004, Pages 2982-2988

  Braga Basaria, Milena ^a   Hardy, Elena ^a   Gottfried, Robert ^a   Burman, Kenneth D ^a   Saji, Motoyasu ^a,b   Ringel, Matthew D ^a,b,c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 MORPHOLINO 8 PHENYLCHROMONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; UNCLASSIFIED DRUG;

CANCER CELL; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; THYROID CARCINOMA; WESTERN BLOTTING;

APOPTOSIS; BENZOQUINONES; CELL DIVISION; CELL LINE, TUMOR; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIFABUTIN; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 2942638038     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031767     Document Type: Conference Paper

References (30)

1. Wynford-Thomas D 1997 Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Horm Res 47:145-157 (Review)
2. Fagin JA 2002 Minireview: branded from the start - distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 16: 903-911
3. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP 2001 Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 22:631-656
4. Coulonval K, Vandeput F, Stein RC, Kozma SC, Lamy F, Dumont JE 2000 Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochem J (Pt 2)348:351-358
5. Specht MC, Barden CB, Fahey 3rd TJ 2001 p44/p42-MAP kinase expression in papillary thyroid carcinomas. Surgery 130:936-940
6. Saito J, Kohn AD, Roth RA, Noguchi Y, Tatsumo I, Hirai A, Suzuki K, Kohn LD, Saji M, Ringel MD 2001 Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid 11:339-351
7. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M 2001 Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61:6105-6111
8. Clément S, Refetoff S, Robaye B, Dumont JE, Schurmans S 2001 Low TSH requirement and goiter in transgenic mice overexpressing IGF-I and IGF-I receptor in the thyroid gland. Endocrinology 142:5131-5266
9. Suh JM, Song JH, Kim DW, Kim H, Chung HK, Hwang JH, Kim JM, Hwang ES, Chung J, Han JH, Cho BY, Ro HK, Shong M 2003 Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland. J Biol Chem 278:21960-21971
10. Höhfeld J, Cyr DM, Patterson C 2001 From the cradle to the grave: molecular chaperones that may choose between folding and degradation. EMBO Rep 2:885-890
11. Young JC, Moarefi I, Hartl FU 2001 Hsp90: a specialized but essential protein-folding tool. J Cell Biol 154:267-273
12. Piatelli MJ, Doughty C, Chiles TC 2002 Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes. J Biol Chem 277:12144-12150
13. Sato S, Fujita N, Tsuruo T 2000 Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97:10832-10837
14. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM 1994 Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91:8324-8328
15. Neckers L 2002 Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55-S61
16. Morishima Y, Kanelakis KC, Murphy PJ, Lowe ER, Jenkins GJ, Osawa Y, Sunahara RK, Pratt WB 2003 The hsp90 cochaperone p23 is the limiting component of the multiprotein hsp90/hsp70-based chaperone system in vivo where it acts to stabilize the client protein: hsp90 complex. J Biol Chem 278: 48754-48763
17. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ 2003 A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410
18. Park J-W, Yeh MW, Wong MG, Lobo M, Hyun WC, Duh Q-Y, Clark OH 2003 The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. J Clin Endocrinol Metab 88: 3346-3353
19. O'Brien MA, Moravec RA, Riss TL 2001 Poly (ADP-ribose) polymerase cleavage monitored in situ in apoptotic cells. Biotechniques 30:886-891
20. Gardner RE, Tuttle RM, Burman KD, Haddady S, Truman C, Sparling YH, Wartofsky L, Sessions RB, Ringel MD 2000 Prognostic importance of vascular invasion in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 126:309-312
21. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290
22. Braga-Basaria M, Ringel MD 2003 Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 88: 1947-1960
23. Grammatikakis N, Vultur A, Ramana CV, Siganou A, Schweinfest CW, Watson DK, Raptis L 2002 The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem 277:8312-8320
24. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA 2001 Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61:4003-4009
25. Stancato LF, Silverstein AM, Owens-Grillo JK, Chow Y-H, Jove R, Pratt WB 1997 The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem 272:4013-4020
26. Zhou Y-G, Gilmore R, Leone G, Coffey MC, Weber B, Lee PWK 2001 Hsp90 phosphorylation is linked to its chaperoning function. J Biol Chem 276:32822-32827
27. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P 1999 DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91: 1940-1999
28. Agnew EB, Wilson RH, Grem JL, Neckers L, Bi D, Takimoto CH 2001 Measurement of the novel antitumor agent 17-(allylamino)-17- demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 755:237-243
29. Mitsiades N, Poulaki V, Mastorakos G, Tseleni-Balafouta S, Kotoula V, Koutras DA, Tsokos M 1999 Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J Clin Endocrinol Metab 84:2924-2932
30. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I 2000 Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 60:4122-4129